Labcorp collaborates with Roche to bring fully automated mass spec to U.S. clinical labs
First U.S. commercial agreement delivers next-generation technology for faster, more accurate diagnostics
5 Feb 2026
Labcorp has announced that it is the first U.S. commercial laboratory with an agreement to implement Roche’s cobas® Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice — accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.
The cobas Mass Spec Solution will first be deployed at Labcorp’s Burlington, North Carolina laboratory, with launch expected in the first quarter of 2026, followed by expansion to additional Labcorp locations.
This agreement builds on Labcorp’s long-standing collaboration with Roche and underscores its commitment to delivering innovative solutions across its Diagnostics and Biopharma Laboratory Services (BLS) business segments.
Historically, mass spectrometry required specialized expertise and manual processes, limiting its use in routine clinical labs. Roche’s cobas® Mass Spec solution changes that by automating the entire workflow — from sample preparation to result interpretation — making these critical tests faster, more reliable, and more widely accessible.
Key features of Roche’s cobas® Mass Spec Solution:
- Fully automated workflow – Eliminates manual steps, reducing complexity and turnaround times
- Broad test menu – Approximately 60 assays to be introduced over time
- Integrated platform – Designed for future integration with clinical chemistry and immunochemistry analyzers
“Labcorp is committed to advancing diagnostic science through transformative technologies,” said Marcia Eisenberg, Ph.D., Labcorp’s chief scientific officer. “Integrating Roche’s automated mass spectrometry solution will enable us to deliver greater accuracy and efficiency for critical tests that guide treatment decisions and improve patient outcomes.”
“This collaboration reflects our shared vision to make advanced diagnostics widely accessible,” said Brad Moore, President and CEO, Roche Diagnostics North America. “Together, we are setting a new benchmark for accuracy, reliability and efficiency in patient care.”
